EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer

Mohamed El-Tanani, Shakta Mani Satyam iD, Sainath Prabhakar, Yahia El-Tanani, Ebrahim Safaii iD, Syed Arman Rabbani, Mark Sutherland

PLOS One · 2026

DOI: 10.1371/journal.pone.0360164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Mohamed El-Tanani und 6 weiteren Autor:innen. Beteiligte Einrichtung: RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Quinazolines, ErbB Receptors, Drug Resistance, Neoplasm. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance to epidermal growth factor receptor (EGFR)-targeted therapy remains a major obstacle in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). This study investigated whether repurposing mebendazole (MBZ), a microtubule-disrupting agent, could restore sensitivity to gefitinib in gefitinib-resistant HCC827 GR5 cells. Gefitinib monotherapy showed minimal cytotoxicity, reducing cell viability only marginally (92.7 ± 1.5%), whereas MBZ significantly decreased viability to 79.7 ± 0.6% at 0.1 µM and 29.7 ± 0.6% at 0.5 µM (p < 0.001). Combination treatment (gefitinib 1 µM + MBZ 0.1 µM) further reduced viability to 37.7 ± 0.6% (p < 0.001). Mechanistically, alkaline comet assay revealed significantly increased single-strand DNA damage in the combination group (tail intensity 22.33 ± 0.56%, p < 0.001), while neutral comet assay confirmed elevated double-strand DNA breaks. MBZ also induced dose-dependent γ-H2AX activation (p < 0.001), supporting replication stress-associated DNA damage signaling. In vivo , combination therapy significantly suppressed tumor growth, prolonging tumor doubling time from 6.2 days in controls to 25 days and increasing growth delay to 18.8 days (p < 0.01), without substantial systemic toxicity. Collectively, these findings identify replication stress vulnerability as a therapeutically exploitable axis and support MBZ repurposing as an adjuvant strategy to overcome gefitinib resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungQuinazolinesErbB ReceptorsDrug Resistance, NeoplasmSignal TransductionLung NeoplasmsMicrotubulesAntineoplastic AgentsGefitinibHumansAnimalsCell Line, TumorMiceCell ProliferationXenograft Model Antitumor AssaysDNA ReplicationMice, NudeCell Survival

Substanzen

GefitinibQuinazolinesErbB ReceptorsAntineoplastic Agents

Autor:innen und Institutionen

  • RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
  • Department of Pharmacology, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
  • Department of Perfusion Technology, Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Royal Cornwall Hospital Trust, NHS, Truro, United Kingdom.
  • Department School of Chemistry and Biomedical Sciences, University of Bradford, Bradford, United Kingdom.

ORCID-Profile: Shakta Mani Satyam, Ebrahim Safaii

Zitieren

APA

El-Tanani, M., Satyam, S. M., Prabhakar, S., El-Tanani, Y., Safaii, E., Rabbani, S. A., & Sutherland, M. (2026). Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer. PLOS One. https://doi.org/10.1371/journal.pone.0360164

Vancouver

El-Tanani M, Satyam SM, Prabhakar S, El-Tanani Y, Safaii E, Rabbani SA, et al. Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer. PLOS One. 2026. doi:10.1371/journal.pone.0360164

BibTeX
@article{ElTanani2026,
  author = {El-Tanani, Mohamed and Satyam, Shakta Mani and Prabhakar, Sainath and El-Tanani, Yahia and Safaii, Ebrahim and Rabbani, Syed Arman and Sutherland, Mark},
  title = {Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0360164}
}
Kostenlos starten →